Protara Therapeutics (NASDAQ:TARA) Announces Earnings Results

Protara Therapeutics (NASDAQ:TARA) posted its earnings results on Monday. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.08, Zacks reports.

Protara Therapeutics Price Performance

Shares of NASDAQ TARA traded up $0.25 during midday trading on Monday, hitting $4.54. The company’s stock had a trading volume of 426,863 shares, compared to its average volume of 367,292. The firm has a market capitalization of $174.97 million, a price-to-earnings ratio of -2.80 and a beta of 1.59. The business’s fifty day simple moving average is $4.35 and its two-hundred day simple moving average is $3.60. Protara Therapeutics has a 1 year low of $2.21 and a 1 year high of $10.48.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.60.

Hedge Funds Weigh In On Protara Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. purchased a new stake in shares of Protara Therapeutics during the second quarter worth $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Protara Therapeutics during the 2nd quarter worth about $53,000. Invesco Ltd. acquired a new stake in Protara Therapeutics in the 2nd quarter valued at about $73,000. New York State Common Retirement Fund purchased a new position in shares of Protara Therapeutics in the 2nd quarter valued at about $102,000. Finally, Rhumbline Advisers grew its position in shares of Protara Therapeutics by 8.2% during the third quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock worth $148,000 after buying an additional 2,596 shares in the last quarter. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.